Multiple Myeloma

>

Latest News

Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.
Mezigdomide Regimens Show Promise in Pretreated R/R Multiple Myeloma

June 19th 2025

Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.

Findings from the phase 1b TRIMM-3 trial support the potential activity of PD-1 inhibition in patients with relapsed/refractory multiple myeloma.
Data Show Enduring Responses With Talquetamab Combo in R/R Multiple Myeloma

June 18th 2025

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM
Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

June 16th 2025

Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.
Subcutaneous Isatuximab Shows Noninferior Efficacy in Multiple Myeloma

June 16th 2025

Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.
Isatuximab Combination Significantly Sustains MRD Negativity in NDMM

June 16th 2025

Latest CME Events & Activities

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

View More

Go To PER in Chicago

May 30, 2025 - June 3, 2025

Register Now!

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

View More

<1
...
6061626364